|
Sino Biological
cetuximab 800cw ![]() Cetuximab 800cw, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+egfr/Human+EGFR+%2F+HER1+%2F+ErbB1+Protein/pmc13652071-347-1-5 Average 94 stars, based on 1 article reviews
cetuximab 800cw - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
TargetMol
egfr ecd ![]() Egfr Ecd, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+egfr/EGFR+Protein%2C+Human%2C+Recombinant/pm42401551-422-11-12 Average 94 stars, based on 1 article reviews
egfr ecd - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Sino Biological
plate ![]() Plate, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+egfr/Human+EGFR+%2F+HER1+%2F+ErbB1+Protein+(His+%26+AVI+Tag)%2C+Biotinylated/pmc13669479-415-2-12 Average 94 stars, based on 1 article reviews
plate - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Bio X Cell
anti human egfr antibody ![]() Anti Human Egfr Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+egfr/InVivoMAb+anti-human+EGFR/pm42849672-100-5-8 Average 93 stars, based on 1 article reviews
anti human egfr antibody - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
ACROBiosystems
egfr extracellular domains ![]() Egfr Extracellular Domains, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+egfr/Biotinylated+Human+EGF+R+Protein%2C+His%2CAvitag/pm42834728-78-5-8 Average 95 stars, based on 1 article reviews
egfr extracellular domains - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
Miltenyi Biotec
pe conjugated egfr antibody ![]() Pe Conjugated Egfr Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+egfr/EGF+Receptor+Antibody%2C+anti-human%2C+REAfinity/pmc13625461-89-14-19 Average 94 stars, based on 1 article reviews
pe conjugated egfr antibody - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Proteintech
human egfr elisa kit ![]() Human Egfr Elisa Kit, supplied by Proteintech, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+egfr/Human+EGFR+ELISA+Kit/pm42803585-143-20-25 Average 88 stars, based on 1 article reviews
human egfr elisa kit - by Bioz Stars,
2026-11
88/100 stars
|
Buy from Supplier |
|
R&D Systems
goat polyclonal r d systems ![]() Goat Polyclonal R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+egfr/Human+EGFR+Antibody/pm42785308-638-256-258 Average 93 stars, based on 1 article reviews
goat polyclonal r d systems - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Sino Biological
pcmv3 egfr ![]() Pcmv3 Egfr, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+egfr/Human+EGFR%2FHER1+Gene+ORF+cDNA+clone+expression+plasmid%2C+C-HA+tag/pm42789385-344-13-15 Average 94 stars, based on 1 article reviews
pcmv3 egfr - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
RayBiotech inc
human egfr phosphorylation antibody array 1 ![]() Human Egfr Phosphorylation Antibody Array 1, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+egfr/Human+EGFR+Phosphorylation+Array+C1/pm42399607-360-7-6 Average 94 stars, based on 1 article reviews
human egfr phosphorylation antibody array 1 - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
Journal: mAbs
Article Title: Tangential flow filtration as a novel approach for fluorescent tracer purification and production up-scaling: cetuximab-800CW and ustekinumab-800CW as a proof-of-concept
doi: 10.1080/19420862.2026.2743444
Figure Lengend Snippet: SE-HPLC chromatograms of cetuximab-800CW purified with PD-10 columns and TFF. Chromatograms after cetuximab-800CW purification using PD-10 columns (A–C) or using TFF (D–F) at (A, D) 280 nm, (B, E) 775 nm, and (C, E) 780 nm.
Article Snippet: For
Techniques: Purification
Journal: mAbs
Article Title: Tangential flow filtration as a novel approach for fluorescent tracer purification and production up-scaling: cetuximab-800CW and ustekinumab-800CW as a proof-of-concept
doi: 10.1080/19420862.2026.2743444
Figure Lengend Snippet: Quality control test results of cetuximab-800CW produced with either the PD-10 column or TFF purification method. Quality controls of TFF and PD-10 bulk productions were compared, and p-values were adjusted for multiple comparisons using the Holm-Šídák method. Label efficiency (Holm-Šídák adjusted p < 0.001) and yield (Holm-Šídák adjusted p=0.021) were compared with Welch’s t-test. Cetuximab-800CW concentration was compared using an independent-samples t-test (Holm-Šídák adjusted p=0.021), and unconjugated IRDye 800CW was compared using a Mann-Whitney U test (Holm-Šídák adjusted p=0.003, Hodges-Lehmann estimate of between-group difference 0.530, CI 0.367-0.751). * = p < 0.05, ** = p < 0.01, *** = p < 0.001.
Article Snippet: For
Techniques: QC/EQA/Proficiency, Produced, Purification, Concentration Assay, Mann-Whitney U-Test, Bioburden Testing
Journal: mAbs
Article Title: Tangential flow filtration as a novel approach for fluorescent tracer purification and production up-scaling: cetuximab-800CW and ustekinumab-800CW as a proof-of-concept
doi: 10.1080/19420862.2026.2743444
Figure Lengend Snippet: Stability data of cetuximab-800CW purified with PD-10 columns or TFF. Release specifications are displayed with dotted lines, and end‑of‑shelf-life specifications are displayed with dashed lines. Stability data of one batch purified with PD-10 and the mean and standard deviation of three batches produced with TFF are shown. For every batch, measurements at each time point are performed in triplicate to quintuplicate. (A) cetuximab-800CW concentration, (B) percentage of free dye, (C) percentage of aggregates, and (D) target binding affinity.
Article Snippet: For
Techniques: Stability, Purification, Standard Deviation, Produced, Concentration Assay, Binding Assay
Journal: mAbs
Article Title: Tangential flow filtration as a novel approach for fluorescent tracer purification and production up-scaling: cetuximab-800CW and ustekinumab-800CW as a proof-of-concept
doi: 10.1080/19420862.2026.2743444
Figure Lengend Snippet: Microscopic analysis (40×) of particle formation. (A) particle formation of ustekinumab-800CW in the technology transfer batch. (B) microscopic picture of a cetuximab-800CW batch with no particles.
Article Snippet: For
Techniques: Analysis
Journal: mAbs
Article Title: Tangential flow filtration as a novel approach for fluorescent tracer purification and production up-scaling: cetuximab-800CW and ustekinumab-800CW as a proof-of-concept
doi: 10.1080/19420862.2026.2743444
Figure Lengend Snippet: Schematic overview of the TFF setup used in the manufacturing of cetuximab-800CW and ustekinumab-800CW. Buffers, antibody, and antibody–dye conjugate are introduced into the feed reservoir to enter the system. The feed reservoir is connected to a filter unit, with tubes leading through a pump to control the flow of the system. The filter unit has two exit ports, one for the permeate, leading to a waste container, and one for the retentate, leading back to the feed reservoir. The permeate tube can be closed to form a closed loop for stabilization of the system, while opening the permeate tube allows the system to start filtering. The TMP is controlled with a clamp and measured with pressure transducers.
Article Snippet: For
Techniques: Control
Journal: mAbs
Article Title: Tangential flow filtration as a novel approach for fluorescent tracer purification and production up-scaling: cetuximab-800CW and ustekinumab-800CW as a proof-of-concept
doi: 10.1080/19420862.2026.2743444
Figure Lengend Snippet: Optimal TFF system parameters for cetuximab-800CW production.
Article Snippet: For
Techniques: Buffer Exchange
Journal: BMC Cancer
Article Title: Co-expression of non-signaling CARs enhances EGFRvIII-specific CAR T-cell cytotoxicity against head and neck squamous cell carcinoma
doi: 10.1186/s12885-026-17058-z
Figure Lengend Snippet: EGFRvIII expression in WT HNSCC cell lines. A Schematic structure of EGFR and EGFRvIII. The EGFRvIII variant is characterized by an in-frame deletion of exons 2–7 in the full-length EGFR gene. The domains of EGFR are shown, labeled domains L1 (also known as domain 1), CR1 (domain 2), L2 (domain 3) and CR2 (domain 4), respectively (adapted from Gan et al. 2009 ). B RT-PCR analysis of EGFRvIII mRNA expression. The presence of EGFRvIII mRNA was assessed in HNSCC cell lines by RT-PCR. A representative ethidium bromide-stained agarose gel shows PCR products for EGFR (1037 bp) and EGFRvIII (236 bp). Primary human fibroblasts (Fibro) served as negative control for EGFRvIII, while DK-MG cells were used as a positive control. Multiple HNSCC cell lines were analyzed. C and D Flow cytometric analysis of EGFRvIII protein expression. Cell lines were stained using a recombinant rabbit monoclonal EGFRvIII antibody followed by a PE-conjugated anti-rabbit IgG (H + L) F(ab’)₂ secondary antibody. EGFR expression was detected using APC- or PE-conjugated human EGFR antibodies. C Relative mean fluorescence intensity (MFI; y-axis) of EGFRvIII and EGFR expression in HNSCC cell lines. EGFRvIII data represent the mean ± SEM of three independent experiments. D Representative histograms of EGFRvIII (red), EGFR (blue), isotype staining with secondary antibody or isotype alone (dark green), and unstained cells (black). Normalized cell count is plotted against the fluorescence intensity
Article Snippet: For sorting of EGFRvIII-positive cells, 5 × 10 6 cells were stained with a
Techniques: Expressing, Variant Assay, Labeling, Reverse Transcription Polymerase Chain Reaction, Analysis, Staining, Agarose Gel Electrophoresis, Negative Control, Positive Control, Recombinant, Fluorescence, Cell Characterization
Journal: BMC Cancer
Article Title: Co-expression of non-signaling CARs enhances EGFRvIII-specific CAR T-cell cytotoxicity against head and neck squamous cell carcinoma
doi: 10.1186/s12885-026-17058-z
Figure Lengend Snippet: Artificial overexpression of EGFRvIII at different levels in HNSCC cell lines. A Schematic representation of the lentiviral EGFRvIII expression vector. The internal promoters (iP: hPGK, hEF1α and SFFV) drive expression of the EGFRvIII transgene and via an IRES site also the Geneticin resistance gene nptII (neoR). B - D UM-14C KO and UT-24A KO cells were transduced with LV EGFRvIII expression vectors. EGFRvIII-positive EGFR KO cells were further purified by flow sorting, generating new EGFRvIII-expressing cell lines. B and C Flow cytometric analysis of EGFRvIII surface expression after sorting. UM-14C and UT-24A cells were stained with ( B ) a PE-conjugated EGFR antibody for EGFR and EGFRvIII expression. Left: EGFR expression is shown by histogram. Right: Means ± SEM of MFI values of EGFRvIII-positive EGFR KO UM-14C and UT-24A cells as well as the corresponding UM-14C and UT-24A KO, WT and control cells transduced with an empty vector (data from three independent experiments) are shown. Differences between promoter groups within each cell line were analyzed using one-way repeated-measures ANOVA followed by Tukey’s multiple-comparisons test. p < 0.05 (*), p < 0.01 (**), p < 0.001 (***); ns, not significant. C EGFRvIII expression was additionally determined using an EGFRvIII-specific recombinant rabbit monoclonal antibody and a PE-conjugated anti-rabbit IgG (H + L) F(ab’)₂ secondary antibody. Data are presented as mean ± SEM from two independent experiments. D RT-PCR analysis of EGFRvIII mRNA expression. Presence of EGFRvIII mRNA was assessed in HNSCC cell lines artificially overexpressing EGFRvIII by RT-PCR. A representative ethidium bromide-stained agarose gel shows PCR products for EGFR (1037 bp) and EGFRvIII (236 bp). WT cell lines (UM-14C WT and UT-24A WT ), their corresponding EGFR KO derivatives, and the three EGFRvIII-overexpressing cell lines generated using different internal promoters were analyzed
Article Snippet: For sorting of EGFRvIII-positive cells, 5 × 10 6 cells were stained with a
Techniques: Over Expression, Expressing, Plasmid Preparation, Transduction, Purification, Analysis, Staining, Control, Recombinant, Reverse Transcription Polymerase Chain Reaction, Agarose Gel Electrophoresis, Generated
Journal: BMC Cancer
Article Title: Co-expression of non-signaling CARs enhances EGFRvIII-specific CAR T-cell cytotoxicity against head and neck squamous cell carcinoma
doi: 10.1186/s12885-026-17058-z
Figure Lengend Snippet: Design, enrichment, and cytotoxicity of CAR-positive T-cells. A Lentiviral CAR expression vector expressing the blue fluorescent protein TagBFP and a 2nd generation CAR construct. The vector contains either CD19, EGFR, or EGFRvIII A–E -specific scFvs, a CD34-derived hinge region (c6) followed by the CD28 transmembrane (TM) and cytoplasmic (CP) domains and the CD3ζ signaling chain. A BFP reporter gene is co-expressed via a T2A sequence. Transgene expression is driven by the MPSV promoter. B Transduction and enrichment efficiency of CAR-positive T-cells. Transduced T-cells were analyzed by flow cytometry before magnetic separation (Pre-MACS), in the flow-through fraction and after MACS selection (Post-MACS). CAR-positive cells were quantified based on BFP co-expression. Representative histograms show CAR expression (x-axis) plotted against normalized cell count (y-axis). CAR-positive cells are shown as mean ± SEM ( n = 3). C CAR T-cell cytotoxicity. The target cell lines UM-14C KO +EGFRvIII high and DK-MG were co-cultured with CD19, EGFR and EGFRvIII A–E CAR T-cells or untransduced T-cells (no virus) for 16 to 20 h and target cell viability was assessed using a luciferase-based viability assay. Target cell lysis according to the E: T ratio (x-axis) is plotted against the percentage of lysed target cells (y-axis). Data represent mean ± SEM of three independent biological experiments using T-cells from independent healthy donors, with n = 5 for UM-14C KO +EGFRvIII high and n = 3 for DK-MG. Statistical analysis was performed using two-way repeated-measures ANOVA across the tested E: T ratios, followed by Dunnett’s multiple-comparisons test versus the CD19 CAR control
Article Snippet: For sorting of EGFRvIII-positive cells, 5 × 10 6 cells were stained with a
Techniques: Expressing, Plasmid Preparation, Construct, Derivative Assay, Sequencing, Transduction, Flow Cytometry, Selection, Cell Characterization, Cell Culture, Virus, Luciferase, Viability Assay, Lysis, Analysis, Control
Journal: BMC Cancer
Article Title: Co-expression of non-signaling CARs enhances EGFRvIII-specific CAR T-cell cytotoxicity against head and neck squamous cell carcinoma
doi: 10.1186/s12885-026-17058-z
Figure Lengend Snippet: CAR T-cell cytotoxicity against different HNSCC cell lines. Different WT and genetically engineered UM-14C/UT-24A cells were co-cultured with CD19, EGFR, EGFRvIII D or EGFRvIII E CAR T-cells or untransduced (no virus) T-cells for 16 to 20 h and target cell viability was assessed using an MTS-based cytotoxicity assay. Target cell lysis at different E: T ratios (x-axis) is plotted against the percentage of lysed target cells (y-axis). Data represent mean ± SEM of three independent biological experiments using T-cells from three independent healthy donors ( n = 3). Statistical analysis was performed using two-way repeated-measures ANOVA across the tested E: T ratios, followed by Dunnett’s multiple-comparisons test versus the CD19 CAR control
Article Snippet: For sorting of EGFRvIII-positive cells, 5 × 10 6 cells were stained with a
Techniques: Cell Culture, Virus, Cytotoxicity Assay, Lysis, Analysis, Control
Journal: BMC Cancer
Article Title: Co-expression of non-signaling CARs enhances EGFRvIII-specific CAR T-cell cytotoxicity against head and neck squamous cell carcinoma
doi: 10.1186/s12885-026-17058-z
Figure Lengend Snippet: Concept, design and cytotoxicity of CAR and nsCAR T-cells. A Schematic representation of CAR/nsCAR co-expression strategies. 2nd generation CARs were combined with non-signaling CARs, which lack signaling domains and provide additional antigen/epitope engagement. B Lentiviral expression vectors encoding CARs or nsCARs. The 2nd generation CAR vector contains either CD44v6, CD33, or EGFRvIII D−E -specific scFvs, the c6-hinge, CD28 transmembrane and cytoplasmic regions, and the CD3ζ chain. An mCherry reporter was co-expressed via a T2A sequence. The nsCAR contains EGFR- or CD19-specific scFvs, the n3-hinge, and the CD8 transmembrane domain. C Killing efficiency of CAR and nsCAR T-cells against WT and genetically engineered UM-14C cells. Primary human T-cells were singly transduced with lentiviral constructs encoding CAR or nsCARs and CAR- or nsCAR-positive T-cells (> 90%) were co-cultured with UM-14C cells for 16 to 20 h and target cell viability was assessed using an MTS-based cytotoxicity assay. Target cell lysis at different E: T ratios (x-axis) is plotted against the percentage of lysed target cells (y-axis). Data represent mean ± SEM of three independent biological experiments using T-cells from three independent healthy donors ( n = 3). Statistical analysis was performed using two-way repeated-measures ANOVA across the tested E: T ratios, followed by Dunnett’s multiple-comparisons test versus the CD33 CAR control
Article Snippet: For sorting of EGFRvIII-positive cells, 5 × 10 6 cells were stained with a
Techniques: Expressing, Plasmid Preparation, Sequencing, Transduction, Construct, Cell Culture, Cytotoxicity Assay, Lysis, Analysis, Control
Journal: BMC Cancer
Article Title: Co-expression of non-signaling CARs enhances EGFRvIII-specific CAR T-cell cytotoxicity against head and neck squamous cell carcinoma
doi: 10.1186/s12885-026-17058-z
Figure Lengend Snippet: Killing efficiency of CAR/nsCAR T-cells. Primary human T-cells were singly or doubly transduced, and CAR-positive T-cells, including CAR/nsCAR double-positive cells, were enriched using CD34 microbeads. Cells were co-cultured with UM-14C cells for 16 to 20 h and target cell viability was assessed using an MTS-based cytotoxicity assay. Target cell lysis at different E: T ratios (x-axis) is plotted against the percentage of lysed target cells (y-axis). Data represent mean ± SEM of three independent biological experiments using T-cells from three independent healthy donors ( n = 3). Statistical analyses were performed using two-way repeated-measures ANOVA across the tested E: T ratios, with donor as the matched experimental unit. Prespecified comparisons assessed the effect of EGFR nsCAR co-expression relative to the corresponding CD19 nsCAR control condition
Article Snippet: For sorting of EGFRvIII-positive cells, 5 × 10 6 cells were stained with a
Techniques: Cell Culture, Cytotoxicity Assay, Lysis, Expressing, Control
Journal: BMC Cancer
Article Title: Co-expression of non-signaling CARs enhances EGFRvIII-specific CAR T-cell cytotoxicity against head and neck squamous cell carcinoma
doi: 10.1186/s12885-026-17058-z
Figure Lengend Snippet: Killing dynamics of CAR/nsCAR T-cells. Primary human T-cells were transduced with an EGFRvIII D/E or CD44v6-specific CAR alone or in combination with additional EGFR- or CD19-specific nsCAR constructs. CAR-positive T-cells, including CAR/nsCAR double-positive cells, were enriched using CD34 microbeads and co-cultured with UM-14C KO +EGFRvIII mid cells for 6, 10, and 20 h and target cell viability was assessed using an MTS-based cytotoxicity assay. Target cell lysis at different E: T ratios (x-axis) is plotted against the percentage of lysed target cells (y-axis). Data represent mean ± SEM of three independent biological experiments using T-cells from three independent healthy donors ( n = 3). Statistical analyses were performed separately for each time point using two-way repeated-measures ANOVA across the tested E: T ratios, with donor as the matched experimental unit. Prespecified comparisons assessed the effect of EGFR nsCAR co-expression relative to the corresponding CD19 nsCAR control condition
Article Snippet: For sorting of EGFRvIII-positive cells, 5 × 10 6 cells were stained with a
Techniques: Transduction, Construct, Cell Culture, Cytotoxicity Assay, Lysis, Expressing, Control
Journal: BMC Cancer
Article Title: Co-expression of non-signaling CARs enhances EGFRvIII-specific CAR T-cell cytotoxicity against head and neck squamous cell carcinoma
doi: 10.1186/s12885-026-17058-z
Figure Lengend Snippet: Visualization of the IS. The IS was analyzed by fluorescence microscopy, visualizing the EGFRvIII D CAR (FITC-conjugated CD34 antibody, green) and EGFR or CD19 nsCAR (PE-Vio770-conjugated NGFR antibody, red) proteins on MACS-enriched CAR/nsCAR T-cells (BFP expression, blue) in relation to UM-14C KO +EGFRvIII high cells (phase contrast). Contrast settings (channels: PH, 377/447 nm, 470/525 nm and 545/620 nm) were adjusted to optimize IS visualization
Article Snippet: For sorting of EGFRvIII-positive cells, 5 × 10 6 cells were stained with a
Techniques: Fluorescence, Microscopy, Expressing, Phase Contrast